A medical researcher with the University of Alberta and his team just published their findings about their work on developing ‘homing beacon drugs’ that kill only cancer cells, not healthy ones, thanks to nano-technology. Read More.
‘Homing Beacon Drugs’ to Target Cancer Cells Read More »
Patients with organ-confined prostate cancer may have a new treatment option using high doses of focused stereotactic body radiotherapy (SBRT) instead of traditional lengthy radiotherapy courses or surgery, according to new data presented at the American Society for Radiation Oncology annual meeting. Read More.
One-Week Radiotherapy Course An Option for Localized PCa Read More »
Men with metastatic castration-resistant prostate cancer (CRPC) lived significantly longer when treated with a bone-targeted, alpha-emitting agent, a randomized trial showed. Read More.
Radium-223 Extends Survival in CRPC Read More »
Long-term quality of life for men who have undergone radical prostatectomy (RP) is inextricably tied to urinary incontinence (UI) issues. Robert K. Nam, MD, MSc, and colleagues helped to shed light on the impact of this side effect by studying rates of UI-corrective surgery occurring up to 15 years following radical prostatectomy. Read More.
UI Surgery Rates Rise Years After RP: An Interview with Robert K. Nam, MD, MSc Read More »
A standard treatment for prostate cancer may change as a result of a new Canadian study that supports “drug holidays” for patients receiving hormone therapy. Read More in the Globe and Mail For a more technical article, click here.
Patients Could Benefit from Intermittent Hormone Therapy Read More »
A widely used breast cancer drug may ease the side effects of prostate cancer treatment, according to a new German study. Scientists examined four studies involving men in Europe and North America undergoing therapy for prostate cancer, the common side effects of which are gynecomastia (breast enlargement) or breast pain. Read More.
Breast cancer drug may ease prostate cancer side effects Read More »
Intermittent androgen deprivation therapy (ADT) has some quality-of-life (QOL) benefits for men with metastatic prostate cancer, but overall survival times are inferior to those seen with continuous ADT, according to the findings of a 17-year study (SWOG9346) presented at the American Society for Clinical Oncology 2012 annual meeting. Read More.
Survival Better with Continuous ADT Read More »
Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel — undetected by normal cells through the bloodstream until activated by specific cancer proteins. The drug, made from a weedlike plant, has been shown to destroy cancers and their direct blood supplies, acting like a “molecular grenade,” and sparing healthy blood vessels and tissues. Read More.
Drug from Mediterranean weed kills tumor cells in mice Read More »
A new study shows that prostate cancer surgery, which often leaves men impotent or incontinent, does not appear to save the lives of men with early-stage disease, who account for most cases, and many of these men would do just as well to choose no treatment at all. From the NY Times And a second article
Questioning Surgery for Early Prostate Cancer Read More »
Dr. Uri Lindner MD, FRCSC Uro-Oncology Fellow Princess Margaret Cancer Centre Toronto, ON, Canada Dr. Lindner is an associate of Dr. John Trachtenberg who has developed a ground-breaking approach to the treatment of prostate cancer. In general approach, this procedure has some similarities to a lumpectomy in the treatment of breast cancer. Despite its recent emergence as an option for treating prostate cancer, MR-guided laser focal therapy for prostate cancer is already earning international attention and attracting increasing interest. CLICK ON THE ARROW TO START THE VIDEO Complete Presentation “MR-guided Laser Focal Therapy for Prostate Cancer.” High Definition 35
VIDEO: Dr. Uri Lindner “MR-guided Laser Focal Therapy for Prostate Cancer.” Read More »